Retatrutide 60mg - Lyophilized Vial
Retatrutide is a multi‑receptor agonist designed to engage incretin and related receptors that regulate appetite, energy expenditure and glucose metabolism. By simultaneously modulating these pathways, it is intended to produce greater weight‑loss and metabolic benefits compared with single‑target agents.
Key Features
- Research‑grade retatrutide with documented purity
- Investigational activity on metabolic pathways relevant to weight management and glycemic control
- Shows potential to reduce body weight and improve metabolic parameters in experimental settings
- May support research into regenerative metabolic therapies and anti‑aging metabolic optimization
- Supplied as lyophilized vial(s) for reconstitution in laboratory environments
Product Specifications
- Product name: Retatrutide (investigational metabolic peptide) (Purity: >99+% HPLC)
- Category: Metabolic / investigational peptide (research)
- Supplied in: Lyophilized powder in sterile vial + 3ml bac water
- Typical administration (research): Subcutaneous injection per protocol
- Storage (reconstituted): Refrigerate at 2 - 8 °C; follow institutional SOPs for validated stability and avoid repeated freeze–thaw cycles
Mechanism of Action
Key Benefits
- Substantial Weight Reduction: Clinical trials demonstrate highly effective weight loss, with higher doses yielding an average reduction of up to 24% body weight in 48 weeks.
- Enhanced Glycemic Control: It significantly lowers HbA1c levels, with early data showing that up to 72% of prediabetic patients achieve normal blood sugar ranges.
- Visceral & Liver Fat Reduction: It promotes a dramatic drop in ectopic fat, potentially reducing liver fat by up to 86% and deep abdominal fat by 48%.
- Metabolic & Cardiovascular Markers: Improves lipid profiles, reduces blood pressure, and helps alleviate systemic inflammation.Potential Organ & Systemic Support: Ongoing studies are exploring its additional benefits for knee osteoarthritis pain, non-alcoholic fatty liver disease (NAFLD), and sleep apnea.
Reconstitution & Dosing Guide
Important: The following examples are for laboratory reference only. Confirm all calculations, aseptic technique and solvent compatibility with your institutional SOPs before use. Adjust volumes and concentrations according to the vial strength provided by your supplier.
Example Reconstitution
Below are straightforward conversions and common dosing examples for a 60 mg vial reconstituted with 3.0 mL bacteriostatic water (resulting concentration: 60 mg ÷ 3.0 mL = 20 mg/mL). Use only for informational/research planning — verify calculations and follow institutional SOPs.
Concentration
- 20 mg/mL (20,000 µg/mL)
Volume-to-dose conversions (mg → mL → U‑100 insulin units)
- 0.4 mg = 0.02 mL = 2 units
- 0.8 mg = 0.04 mL = 4 units
- 1.2 mg = 0.06 mL = 6 units
- 1.6 mg = 0.08 mL = 8 units
- 2.0 mg = 0.10 mL = 10 units
Range and Frequency
Starting / low exploratory dose: approximately 0.4 mg (400 µg) once daily
Typical escalation steps: 0.4 → 0.8 → 1.2 → 1.6 → 2.0 → 2.4 mg (increments and cadence depend on protocol)
Dosing frequency in studies: once daily subcutaneous injection
Typical Titration Approach in Trials
Use a conservative starting dose (e.g., 0.4 mg/day) and predefined titration steps in your protocol.
Allow 1–4 weeks between dose escalations to assess tolerability; length depends on the expected side‑effect profile and study design.
Define stopping rules for adverse events and criteria for dose reduction.
Monitor weight, appetite, GI symptoms, blood glucose, and any other protocol‑specified biomarkers.
Cycle Length and Duration
Treatment periods in trials commonly range from 12 weeks up to 48 weeks depending on endpoints; early‑phase dose‑finding cohorts often use 4–12 week blocks per dose level.
There is typically no short “on/off” cycling; continuous daily dosing is the norm while titrating.
Safety / Tolerability Notes
- Beneficial effects: reduced appetite, weight loss, improved glycemic markers and insulin sensitivity and changes in energy expenditure.
- Possible adverse events: gastrointestinal symptoms, transient headache, injection‑site reactions and glycemic changes. Monitor for hypoglycemia if combined with other glucose‑lowering agents.
- Document and monitor all adverse events according to institutional safety procedures.
Administration Notes
- Subcutaneous injection is the typical route in research protocols; timing (morning vs evening), frequency, and titration depend on study aims and safety data.
- Consider gradual dose escalation protocols to monitor tolerability and metabolic responses.
Cycle Length and Scheduling
- Cycle lengths vary by study design; many metabolic peptide studies use daily or weekly dosing schedules depending on pharmacokinetics.
- Tapering may not be required but should be defined in the protocol to minimize rebound effects.
Handling, Stability and Storage After Reconstitution
- Reconstituted solutions: refrigerate (2–8 °C)
- Use aseptic technique, sterile syringes and needles for preparation and dosing.
Frequently Asked Questions
Q: What dose should be used?
A: Dose selection must be based on supplier potency data, preclinical pharmacology, and an approved study protocol. Begin with conservative doses and escalate carefully under monitoring.
Q: How is retatrutide administered?
A: Subcutaneous injection is standard in research; alternative routes depend on formulation and experimental design.
Q: Can it be combined with other metabolic agents?
A: Combination studies are common but require careful monitoring for additive effects on glucose and other systems.
Legal and Regulatory Notice
By purchasing this product you confirm that you are acquiring it for lawful research purposes. It is the purchaser’s responsibility to ensure compliance with local laws, institutional policies, ethical and customs requirements. Liability for misuse is disclaimed.
